Market research
NV9.F Kazia Therapeutics Limited
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 102M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.98
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 102M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.98
About
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NV9.F discussion.
5 years, 5 months ago
Kazia Therapeutics Limited is currently in a long term uptrend where the price is trading 6.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kazia Therapeutics Limited's total revenue sank by 0.0% to $313K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 348.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Kazia Therapeutics Limited gets an overall score of 2/5.